High Risk Cardiac Revascularization
Text examines and compares medical and surgical management of cardiovascular disease for the high-risk cardiac patient. Includes comprehensive coverage of trials along with an examination of evolving medical technology. A resource for cardiologists, cardiac surgeons, and trainees. Contains more than 100 halftone illustrations.
| Author: |
Douglass A Morrison, Patric W Serruys |
| ISBN: |
1841841854 |
| Publisher: |
Martin Dunitz Publishing |
| Binding: |
Hardcover |
| Year Published: |
Oct 2002 |
| No. of Pages: |
592 |
| Illustrations: |
105 |
| Contents: |
1. An interventionalist's perspective
2. A cardiac surgeon's perspective.
Section I: Is the medical management optimal?
3. What constitutes medically refractory in the new millennium?
4. Beta-blocking agents
5. Statins and other lipid-lowering agents
6. Angiotensin-converting enzyme inhibitors
7. Anticoagulants in unstable angina and acute myocardial infarction Antiplatelet therapy
Section II: The benefits of revascularization
8. To prolong a life: summary of the Coronary Bypass Trials
9. To improve a life: relief of symptoms, exercise tolerance, ACME and RITA-2 Rationale and design for the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
10. Results of randomised controlled trials in patients with non-ST segment elevation acute coronary syndromes (TIMI-IIIB, VANQWISH, FRISC-II, TACTICS TIMI-18)
Section III: Comparative trials of CABG versus PCI
11. The RITA trials
12. Emory angioplasty vs surgery trial
13. Percutaneous coronary intervention and coronary bypass surgery in high-risk patients: a look from the South
14. The MASS trials
15. The Awesome trials
16. Randomized comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease
Section IV: Differential risks/differential benefits: patient subsets
18. Re-operative revascularization
19. Elective stenting of left main coronary artery disease
20. Coronary interventions in acute myocardial infarction
21. Acute myorcardial infarction: SMASH perspective
22. Cardiogenic shock: SHOCK trial perspective
23. Cardiogenic shock: a VA perspective
24. Chronic occlusions
Section V: Comorbidity
26. Chronic pulmonary disease
27. Cerebrovascular and peripheral vascular comorbidity Liver disease
28. Renal function and high-risk coronary artery procedures
29. High-risk coronary interventions in diabetic patients
Section VI: Adding value to the revascularization option
30. Off-pump coronary artery bypass in high-risk patients
31. Support for percutaneous coronary interventions: IABP, CPS and beyond
32. Stents and high-risk cardiac revascularization
33. Pharmacologic support for PCI: glycoprotein IIb/IIIa receptor blockers
34. Myocardial protection for high-risk coronary surgery
Section VII: What can be done after the revascularization to discourage recidivism?
35. Cardiac rehabilitation
Section VIII: Medicine vs PCI vs CABG in 2001 for high-risk unstable angina
36. Cost comparisons of PTCA vs CABG
37. High-risk myocardial ischemia in 2002: medicine, PCI and CABG |
|
|
|
Please note
Publishers prices can change unexpectedly. If the price of your book has changed we will contact you.
|
